1 line
17 KiB
Plaintext
1 line
17 KiB
Plaintext
{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T15:23:09Z","timestamp":1701098589572},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","thegreenjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.radonc.2023.109464","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T16:11:03Z","timestamp":1673453463000},"page":"109464","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Overcoming inter-observer planning variability in target volume contouring and dose planning for high-risk neuroblastoma \u2013 a European multicenter effort of the SIOPEN radiotherapy committee"],"prefix":"10.1016","volume":"181","author":[{"given":"Danny","family":"Jazmati","sequence":"first","affiliation":[]},{"given":"Lorenzo","family":"Brualla","sequence":"additional","affiliation":[]},{"given":"Annemieke S","family":"Littooij","sequence":"additional","affiliation":[]},{"given":"Britta","family":"Webber","sequence":"additional","affiliation":[]},{"given":"Karin","family":"Dieckmann","sequence":"additional","affiliation":[]},{"given":"Geert O","family":"Janssens","sequence":"additional","affiliation":[]},{"given":"Thorsten","family":"Simon","sequence":"additional","affiliation":[]},{"given":"Mark N.","family":"Gaze","sequence":"additional","affiliation":[]},{"given":"Julien","family":"Merta","sequence":"additional","affiliation":[]},{"given":"Antonio","family":"Serrano","sequence":"additional","affiliation":[]},{"given":"Stefan","family":"Dietzsch","sequence":"additional","affiliation":[]},{"given":"Paul-Heinz","family":"Kramer","sequence":"additional","affiliation":[]},{"given":"J\u00f6rg","family":"Wulff","sequence":"additional","affiliation":[]},{"given":"Tom","family":"Boterberg","sequence":"additional","affiliation":[]},{"given":"Beate","family":"Timmermann","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2023.109464_b0005","first-page":"297","article-title":"Neuroblastoma","volume":"58","author":"Colon","year":"2011","journal-title":"Adv Pediatr Infect Dis"},{"key":"10.1016\/j.radonc.2023.109464_b0010","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2008.16.6785","article-title":"The international neuroblastoma risk group (INRG) classification system: an INRG task force report","volume":"27","author":"Cohn","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109464_b0015","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2008.16.6876","article-title":"The international neuroblastoma risk group (INRG) staging system: an INRG task force report","volume":"27","author":"Monclair","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109464_b0020","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1200\/JCO.20.03144","article-title":"Randomized trial of two induction therapy regimens for high-risk neuroblastoma: HR-NBL1.5 international society of pediatric oncology European neuroblastoma group study","volume":"39","author":"Garaventa","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109464_b0025","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1200\/JCO.19.03117","article-title":"Influence of surgical excision on the survival of patients with stage 4 high-risk neuroblastoma: a report from the HR-NBL1\/SIOPEN study","volume":"38","author":"Holmes","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109464_b0030","doi-asserted-by":"crossref","first-page":"E309","DOI":"10.3390\/cancers12020309","article-title":"Investigation of the role of dinutuximab beta-based immunotherapy in the SIOPEN high-risk neuroblastoma 1 trial (HR-NBL1)","volume":"12","author":"Ladenstein","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.radonc.2023.109464_b0035","article-title":"The evidence for external beam radiotherapy in high-risk neuroblastoma of childhood: a systematic review","author":"Arumugam","year":"2018","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109464_b0040","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S1470-2045(17)30070-0","article-title":"Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1\/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial","volume":"18","author":"Ladenstein","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109464_b0045","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijrobp.2012.05.004","article-title":"Results of a quality assurance review of external beam radiation therapy in the International Society of Paediatric Oncology (Europe) Neuroblastoma Group\u2019s High-risk Neuroblastoma Trial: a SIOPEN study","volume":"85","author":"Gaze","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109464_b0050","doi-asserted-by":"crossref","unstructured":"de Rojas T., Clementel E., Giralt J., Cruz O., Boterberg T., Kortmann R.-D., et al; SIOP-Europe QUARTET Project and of the EORTCRadiotherapy practice for paediatric brain tumours across Europe and quality assurance initiatives: Current situation, international survey and future perspectives. Eur J Cancer. 2019 Jun;114:36-46. doi: 10.1016\/j.ejca.2019.03.018. Epub 2019 Apr 28","DOI":"10.1016\/j.ejca.2019.03.018"},{"key":"10.1016\/j.radonc.2023.109464_b0055","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.oraloncology.2018.11.014","article-title":"Radiation therapy quality assurance in head and neck radiotherapy - moving forward","volume":"88","author":"McDowell","year":"2019","journal-title":"Oral Oncol"},{"key":"10.1016\/j.radonc.2023.109464_b0065","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.radonc.2010.08.017","article-title":"Development of an electronic database for quality assurance of radiotherapy in the International Society of Paediatric Oncology (Europe) high risk neuroblastoma study","volume":"97","author":"Gaze","year":"2010","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.radonc.2023.109464_b0070","first-page":"209","article-title":"QUARTET: a SIOP Europe project for quality and excellence in radiotherapy and imaging for children and adolescents with cancer","volume":"2022","author":"Kelly","year":"1990","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2023.109464_b0080","unstructured":"The Measurement of Observer Agreement for Categorical Data on JSTOR n.d. https:\/\/www.jstor.org\/stable\/2529310 (accessed February 2, 2022)."},{"key":"10.1016\/j.radonc.2023.109464_b0085","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.radonc.2010.06.009","article-title":"Tools for consensus analysis of experts\u2019 contours for radiotherapy structure definitions","volume":"97","author":"Allozi","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109464_b0090","unstructured":"Tools for Consensus Analysis of Experts\u2019 Contours for Radiotherapy Structure Definitions n.d. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3116271\/ (accessed February 2, 2022)."},{"key":"10.1016\/j.radonc.2023.109464_b0095","doi-asserted-by":"crossref","first-page":"e575","DOI":"10.1097\/SLA.0000000000003947","article-title":"A novel standard for systematic reporting of neuroblastoma surgery: the international neuroblastoma surgical report form (INSRF): a joint initiative by the pediatric oncological cooperative groups SIOPEN\u2217, COG\u2217\u2217, and GPOH\u2217\u2217\u2217","volume":"275","author":"Matthyssens","year":"2022","journal-title":"Ann Surg"},{"key":"10.1016\/j.radonc.2023.109464_b0100","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.clon.2005.03.004","article-title":"Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing\u2019s sarcoma: a review of the literature and implications for practice","volume":"17","author":"Seddon","year":"2005","journal-title":"Clin Oncol R Coll Radiol G B"},{"key":"10.1016\/j.radonc.2023.109464_b0105","article-title":"High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008","volume":"JCO2018782516.","author":"Whelan","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109464_b0110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00066-009-1009-9","article-title":"Radiation toxicity following busulfan\/melphalan high-dose chemotherapy in the EURO-EWING-99-trial: review of GPOH data","volume":"185","author":"B\u00f6lling","year":"2009","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2023.109464_b0115","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/j.ijrobp.2020.07.1513","article-title":"Contouring variability in pediatric abdominal neuroblastoma: results of a national quality assurance exercise","volume":"108","author":"Smyth","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109464_b0120","doi-asserted-by":"crossref","unstructured":"Liu KX, Naranjo A, Zhang FF, DuBois SG, Braunstein SE, Voss SD, et al. Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children\u2019s Oncology Group ANBL0532 Study. J Clin Oncol 2020:JCO.19.03316. https:\/\/doi.org\/10.1200\/JCO.19.03316","DOI":"10.1200\/JCO.19.03316"},{"key":"10.1016\/j.radonc.2023.109464_b0125","doi-asserted-by":"crossref","first-page":"e27009","DOI":"10.1002\/pbc.27009","article-title":"Dose-escalation is needed for gross disease in high-risk neuroblastoma","volume":"65","author":"Casey","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.radonc.2023.109464_b0130","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/S1470-2045(19)30034-8","article-title":"Management of vertebral radiotherapy dose in paediatric patients with cancer: consensus recommendations from the SIOPE radiotherapy working group","volume":"20","author":"Hoeben","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109464_b0135","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2217\/fon.12.199","article-title":"Intensity-modulated arc therapy to improve radiation dose delivery in the treatment of abdominal neuroblastoma","volume":"9","author":"Gains","year":"2013","journal-title":"Future Oncol"},{"key":"10.1016\/j.radonc.2023.109464_b0140","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ijrobp.2009.09.040","article-title":"Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues","volume":"76","author":"Bentzen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109464_b0145","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.clon.2019.01.002","article-title":"Pediatric normal tissue effects in the clinic (PENTEC): an international collaboration to analyse normal tissue radiation dose-volume response relationships for paediatric cancer patients","volume":"31","author":"Constine","year":"2019","journal-title":"Clin Oncol R Coll Radiol G B"},{"key":"10.1016\/j.radonc.2023.109464_b0150","article-title":"The HARMONIC project: study design for the assessment of radiation doses and associated cancer risks following cardiac fluoroscopy in childhood","volume":"40","author":"Harbron","year":"2020","journal-title":"J Radiol Prot"},{"key":"10.1016\/j.radonc.2023.109464_b0155","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(05)70291-6","article-title":"Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial","volume":"6","author":"Berthold","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109464_b0170","article-title":"Proton beam therapy for children with neuroblastoma: experiences from the prospective KiProReg registry","volume":"10","author":"Jazmati","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2023.109464_b0175","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26732","article-title":"Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series","volume":"65","author":"Ding","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.radonc.2023.109464_b0180","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ijrobp.2019.01.095","article-title":"Outcomes after proton therapy for treatment of pediatric high-risk neuroblastoma","volume":"104","author":"Hill-Kayser","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109464_b0185","doi-asserted-by":"crossref","first-page":"e27786","DOI":"10.1002\/pbc.27786","article-title":"Efficacy of proton therapy in children with high-risk and locally recurrent neuroblastoma","volume":"66","author":"Bagley","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.radonc.2023.109464_b0190","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.phro.2021.06.003","article-title":"Risk of radiation-induced second malignant neoplasms from photon and proton radiotherapy in paediatric abdominal neuroblastoma","volume":"19","author":"Taylor","year":"2021","journal-title":"Phys Imaging Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.109464_b0060","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00066-019-01469-y","article-title":"A dedicated cloud system for real-time upfront quality assurance in pediatric radiation therapy","volume":"195","author":"Meroni","year":"2019","journal-title":"Strahlenther Onkol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023000026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023000026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T20:06:05Z","timestamp":1688241965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814023000026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":35,"alternative-id":["S0167814023000026"],"URL":"http:\/\/dx.doi.org\/10.1016\/j.radonc.2023.109464","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":["Radiology, Nuclear Medicine and imaging","Oncology","Hematology"],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming inter-observer planning variability in target volume contouring and dose planning for high-risk neuroblastoma \u2013 a European multicenter effort of the SIOPEN radiotherapy committee","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109464","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109464"}} |